Malta - angličtina - Medicines Authority

boehringer ingelheim limited - ipratropium bromide - pressurised inhalation, solution - ipratropium bromide 20 µg - drugs for obstructive airway diseases

Velká Británie - angličtina - MHRA (Medicines & Healthcare Products Regulatory Agency)

boehringer ingelheim ltd - ipratropium bromide - pressurised inhalation - 20microgram/1dose

Malajsie - angličtina - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

glaxosmithkline pharmaceutical sdn. bhd. - fluticasone propionate -

Malajsie - angličtina - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

glaxosmithkline pharmaceutical sdn. bhd. - fluticasone propionate -

Irsko - angličtina - HPRA (Health Products Regulatory Authority)

ayrton saunders (ireland) limited - glyceryl trinitrate - sublingual spray, solution - 0.7%w/w percent weight/weight - organic nitrates; glyceryl trinitrate

Kanada - angličtina - Health Canada

jubilant draximage inc. dba jubilant radiopharma - tetrakis [cu(mibi)4]bf4 - powder for solution - 1mg - tetrakis [cu(mibi)4]bf4 1mg - diagnostic agents

Evropská unie - angličtina - EMA (European Medicines Agency)

accord healthcare s.l.u. - docetaxel - head and neck neoplasms, carcinoma, non-small-cell lung, adenocarcinoma, prostatic neoplasms, breast neoplasms - antineoplastic agents, - breast cancerdocetaxel accord in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with:operable node-positive breast cancer;operable node-negative breast cancer.for patients with operable node-negative breast cancer, adjuvant treatment should be restricted to patients eligible to receive chemotherapy according to internationally established criteria for primary therapy of early breast cancer.docetaxel accord in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition.docetaxel accord monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic therapy. previous chemotherapy should have included an anthracycline or an alkylating agent.docetaxel accord in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer w

Velká Británie - angličtina - MHRA (Medicines & Healthcare Products Regulatory Agency)

accord healthcare ltd - docetaxel - solution for infusion - 20mg/1ml